Entrada Therapeutics (TRDA)
Entrada Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
3.3M
Short interest
settlement 2026-10-15
8.6
Days to cover
-1.3 days vs prior
29.3%
Short share of volume
2026-11-03
47,862
Fails to deliver
settlement 2026-10-05
Thu 5 Nov
Next earnings
estimated date
-$8.7M
Insider flow, 90 days
0 buys, 29 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in TRDA is 3,271,781 shares, up 527,636 shares over the last month. Over the last 48 readings it ranged from 760,344 shares (31 December 2025) to 3,271,781 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 381K shares a day that is 8.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/trda" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 3,271,781 | +9.4% | 380,605 | 8.60 |
| 2026-09-30 | 2,989,455 | +8.9% | 303,169 | 9.86 |
| 2026-09-15 | 2,744,145 | +17.0% | 340,415 | 8.06 |
| 2026-08-31 | 2,345,803 | -0.9% | 219,451 | 10.69 |
| 2026-08-14 | 2,367,019 | +10.4% | 384,854 | 6.15 |
| 2026-07-31 | 2,143,736 | -3.9% | 494,747 | 4.33 |
| 2026-07-15 | 2,230,697 | +5.6% | 356,582 | 6.26 |
| 2026-06-30 | 2,111,685 | +10.4% | 360,809 | 5.85 |
| 2026-06-15 | 1,913,294 | +10.8% | 239,128 | 8.00 |
| 2026-05-29 | 1,727,002 | +14.5% | 386,626 | 4.47 |
| 2026-05-15 | 1,507,737 | +51.0% | 972,065 | 1.55 |
| 2026-04-30 | 998,352 | +17.1% | 182,150 | 5.48 |
| 2026-04-15 | 852,247 | -4.7% | 154,155 | 5.53 |
| 2026-03-31 | 894,152 | -3.3% | 190,100 | 4.70 |
| 2026-03-13 | 924,265 | +12.3% | 264,152 | 3.50 |
| 2026-02-27 | 822,864 | -9.5% | 171,223 | 4.81 |
| 2026-02-13 | 908,901 | +1.4% | 195,458 | 4.65 |
| 2026-01-30 | 896,142 | +4.4% | 286,600 | 3.13 |
| 2026-01-15 | 858,462 | +12.9% | 218,611 | 3.93 |
| 2025-12-31 | 760,344 | -15.4% | 174,083 | 4.37 |
| 2025-12-15 | 898,798 | -5.3% | 184,643 | 4.87 |
| 2025-11-28 | 948,628 | +2.4% | 253,092 | 3.75 |
| 2025-11-14 | 926,483 | +3.7% | 348,857 | 2.66 |
| 2025-10-31 | 893,790 | -5.3% | 187,084 | 4.78 |
| 2025-10-15 | 944,223 | +16.1% | 171,990 | 5.49 |
| 2025-09-30 | 813,393 | -22.9% | 491,778 | 1.65 |
| 2025-09-15 | 1,055,611 | -2.3% | 278,730 | 3.79 |
| 2025-08-29 | 1,080,683 | +1.1% | 172,426 | 6.27 |
| 2025-08-15 | 1,068,552 | -6.7% | 327,197 | 3.27 |
| 2025-07-31 | 1,145,776 | -11.7% | 147,064 | 7.79 |
| 2025-07-15 | 1,297,778 | +3.7% | 145,173 | 8.94 |
| 2025-06-30 | 1,251,732 | +13.5% | 163,944 | 7.64 |
| 2025-06-13 | 1,102,626 | +0.8% | 110,420 | 9.99 |
| 2025-05-30 | 1,093,565 | +3.6% | 156,227 | 7.00 |
| 2025-05-15 | 1,055,797 | -0.8% | 126,666 | 8.34 |
| 2025-04-30 | 1,064,185 | -3.1% | 143,404 | 7.42 |
| 2025-04-15 | 1,098,052 | -5.8% | 207,659 | 5.29 |
| 2025-03-31 | 1,166,191 | -5.4% | 96,430 | 12.09 |
| 2025-03-14 | 1,232,322 | -11.0% | 127,024 | 9.70 |
| 2025-02-28 | 1,384,534 | -8.9% | 123,171 | 11.24 |
| 2025-02-14 | 1,520,260 | -9.3% | 100,809 | 15.08 |
| 2025-01-31 | 1,677,096 | -10.8% | 114,565 | 14.64 |
| 2025-01-15 | 1,879,083 | +2.3% | 131,205 | 14.32 |
| 2024-12-31 | 1,837,237 | +12.1% | 116,995 | 15.70 |
| 2024-12-13 | 1,639,656 | +7.4% | 122,043 | 13.44 |
| 2024-11-29 | 1,526,416 | -5.0% | 94,425 | 16.17 |
| 2024-11-15 | 1,607,420 | -3.4% | 180,588 | 8.90 |
| 2024-10-31 | 1,664,526 | +0.6% | 71,816 | 23.18 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of TRDA volume is 29.3%, up 10.2 points over the last five sessions. Over the last 30 readings it ranged from 19.1% (27 October 2026) to 67.4% (1 October 2026). The latest reading is 17.1 points below the 30-session average of 46.4%, on 150K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 44K | 150K | 29.3% | 316 |
| 2026-11-02 | 198K | 311K | 63.7% | 10,496 |
| 2026-10-30 | 56K | 118K | 47.3% | 5,123 |
| 2026-10-29 | 39K | 168K | 23.1% | 1 |
| 2026-10-28 | 65K | 175K | 36.9% | 0 |
| 2026-10-27 | 25K | 133K | 19.1% | 0 |
| 2026-10-26 | 117K | 271K | 43.2% | 0 |
| 2026-10-23 | 33K | 67K | 50.0% | 3 |
| 2026-10-22 | 105K | 170K | 62.2% | 0 |
| 2026-10-21 | 44K | 120K | 36.9% | 0 |
| 2026-10-20 | 69K | 147K | 46.9% | 0 |
| 2026-10-19 | 104K | 264K | 39.4% | 409 |
| 2026-10-16 | 45K | 117K | 38.5% | 7 |
| 2026-10-15 | 113K | 177K | 63.7% | 386 |
| 2026-10-14 | 147K | 313K | 47.0% | 21,286 |
| 2026-10-13 | 19K | 60K | 32.4% | 12 |
| 2026-10-12 | 33K | 75K | 44.1% | 0 |
| 2026-10-09 | 35K | 68K | 52.0% | 0 |
| 2026-10-08 | 53K | 89K | 58.8% | 0 |
| 2026-10-07 | 78K | 132K | 59.2% | 0 |
| 2026-10-06 | 73K | 138K | 52.7% | 0 |
| 2026-10-05 | 80K | 190K | 41.8% | 1,110 |
| 2026-10-02 | 77K | 144K | 53.4% | 765 |
| 2026-10-01 | 96K | 142K | 67.4% | 311 |
| 2026-09-30 | 38K | 77K | 48.6% | 0 |
| 2026-09-29 | 26K | 66K | 39.8% | 0 |
| 2026-09-28 | 59K | 121K | 48.9% | 0 |
| 2026-09-25 | 69K | 122K | 56.7% | 0 |
| 2026-09-24 | 71K | 143K | 49.9% | 0 |
| 2026-09-23 | 44K | 110K | 39.6% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 5 October 2026, the fails-to-deliver balance in TRDA is 47,862 shares, up 47,583 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (29 July 2026) to 54,878 shares (3 March 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-05 | 47,862 | $5.38 | $257K |
| 2026-09-04 | 279 | $7.17 | $2K |
| 2026-08-19 | 177 | $7.27 | $1K |
| 2026-08-04 | 2,003 | $7.26 | $15K |
| 2026-07-29 | 1 | $5.83 | $6 |
| 2026-07-23 | 1,068 | $6.15 | $7K |
| 2026-06-15 | 13 | $6.46 | $84 |
| 2026-05-04 | 11,816 | $14.50 | $171K |
| 2026-04-09 | 8,044 | $14.32 | $115K |
| 2026-04-02 | 634 | $13.48 | $9K |
| 2026-03-17 | 2,121 | $12.74 | $27K |
| 2026-03-04 | 16,937 | $11.85 | $201K |
| 2026-03-03 | 54,878 | $11.68 | $641K |
| 2026-01-22 | 673 | $11.30 | $8K |
| 2025-12-22 | 200 | $10.98 | $2K |
| 2025-11-24 | 48 | $10.11 | $485 |
| 2025-10-17 | 444 | $6.18 | $3K |
| 2025-10-14 | 750 | $5.81 | $4K |
| 2025-09-17 | 943 | $5.12 | $5K |
| 2025-09-12 | 66 | $5.33 | $352 |
| 2025-09-10 | 416 | $5.14 | $2K |
| 2025-08-21 | 688 | $5.31 | $4K |
| 2025-08-18 | 900 | $5.27 | $5K |
| 2025-08-01 | 1,217 | $5.88 | $7K |
| 2025-07-28 | 2,000 | $6.54 | $13K |
| 2025-07-22 | 741 | $6.14 | $5K |
| 2025-07-21 | 401 | $6.26 | $3K |
| 2025-07-14 | 27,000 | $6.55 | $177K |
| 2025-07-11 | 27,000 | $6.76 | $183K |
| 2025-07-10 | 27,000 | $7.57 | $204K |
Insider trades
SEC Form 4, newest first. JSONInsiders at TRDA reported 29 open-market sells worth $8.7M in the last 90 days and no open-market buys. Latest filing: MPM BIOVENTURES 2018, L.P. (10% owner) on 2026-09-09.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-09 | MPM BIOVENTURES 2018, L.P. | 10% owner | Sell | 29K | $7.13 | $206K | 3.9M |
| 2026-09-09 | MPM BioVentures 2014, L.P. | 10% owner | Sell | 29K | $7.13 | $206K | 3.9M |
| 2026-09-08 | MPM BIOVENTURES 2018, L.P. | 10% owner | Sell | 193K | $7.41 | $1.4M | 3.9M |
| 2026-09-08 | MPM BioVentures 2014, L.P. | 10% owner | Sell | 193K | $7.41 | $1.4M | 3.9M |
| 2026-09-04 | MPM BIOVENTURES 2018, L.P. | 10% owner | Sell | 39K | $7.11 | $274K | 4.1M |
| 2026-09-04 | MPM BioVentures 2014, L.P. | 10% owner | Sell | 39K | $7.11 | $274K | 4.1M |
| 2026-09-03 | MPM BIOVENTURES 2018, L.P. | 10% owner | Sell | 32K | $7.17 | $231K | 4.1M |
| 2026-09-03 | MPM BioVentures 2014, L.P. | 10% owner | Sell | 32K | $7.17 | $231K | 4.1M |
| 2026-09-02 | Sethuraman Natarajan | President, Research & Develop. | Tax withholding | 2K | $7.14 | $15K | 214K |
| 2026-09-02 | WENTWORTH KORY JAMES | Chief Financial Officer | Tax withholding | 2K | $7.14 | $12K | 117K |
| 2026-09-02 | MPM BIOVENTURES 2018, L.P. | 10% owner | Sell | 25K | $7.19 | $181K | 4.2M |
| 2026-09-02 | MPM BioVentures 2014, L.P. | 10% owner | Sell | 25K | $7.19 | $181K | 4.2M |
| 2026-09-02 | Dowden Nathan J | President & COO | Tax withholding | 3K | $7.14 | $18K | 196K |
| 2026-09-02 | Doshi Dipal | CEO | Tax withholding | 9K | $7.14 | $62K | 517K |
| 2026-09-01 | MPM BIOVENTURES 2018, L.P. | 10% owner | Sell | 29K | $7.06 | $205K | 4.2M |
| 2026-09-01 | MPM BioVentures 2014, L.P. | 10% owner | Sell | 29K | $7.06 | $205K | 4.2M |
| 2026-08-31 | MPM BIOVENTURES 2018, L.P. | 10% owner | Sell | 44K | $6.99 | $309K | 4.2M |
| 2026-08-31 | MPM BioVentures 2014, L.P. | 10% owner | Sell | 44K | $6.99 | $309K | 4.2M |
| 2026-08-28 | MPM BIOVENTURES 2018, L.P. | 10% owner | Sell | 4K | $7.01 | $26K | 4.3M |
| 2026-08-28 | MPM BioVentures 2014, L.P. | 10% owner | Sell | 4K | $7.01 | $26K | 4.3M |
| 2026-08-27 | MPM BIOVENTURES 2018, L.P. | 10% owner | Sell | 39K | $7.20 | $280K | 4.3M |
| 2026-08-27 | MPM BioVentures 2014, L.P. | 10% owner | Sell | 39K | $7.20 | $280K | 4.3M |
| 2026-08-26 | MPM BIOVENTURES 2018, L.P. | 10% owner | Sell | 15K | $7.06 | $103K | 4.3M |
| 2026-08-26 | MPM BioVentures 2014, L.P. | 10% owner | Sell | 15K | $7.06 | $103K | 4.3M |
| 2026-08-25 | MPM BIOVENTURES 2018, L.P. | 10% owner | Sell | 27K | $7.54 | $200K | 4.3M |
| 2026-08-25 | MPM BioVentures 2014, L.P. | 10% owner | Sell | 27K | $7.54 | $200K | 4.3M |
| 2026-08-24 | MPM BIOVENTURES 2018, L.P. | 10% owner | Sell | 22K | $7.34 | $159K | 4.4M |
| 2026-08-24 | MPM BioVentures 2014, L.P. | 10% owner | Sell | 22K | $7.34 | $159K | 4.4M |
| 2026-08-10 | PARMAR KUSH | Director | Sell | 92K | $7.00 | $647K | 2.7M |
| 2026-08-07 | PARMAR KUSH | Director | Sell | 52K | $6.85 | $358K | 2.8M |
| 2026-08-07 | 5AM Ventures V, L.P. | 10% owner | Sell | 52K | $6.85 | $358K | 2.8M |
| 2026-08-06 | PARMAR KUSH | Director | Sell | 10K | $7.00 | $73K | 2.8M |
| 2026-08-06 | 5AM Ventures V, L.P. | 10% owner | Sell | 10K | $7.00 | $73K | 2.8M |
| 2026-07-31 | PARMAR KUSH | Director, 10% owner | Sell | 2K | $6.85 | $12K | 2.8M |
| 2026-07-31 | 5AM Ventures V, L.P. | 10% owner | Sell | 2K | $6.85 | $12K | 2.8M |
| 2026-07-30 | PARMAR KUSH | Director, 10% owner | Sell | 115K | $6.93 | $795K | 2.8M |
| 2026-07-30 | 5AM Ventures V, L.P. | 10% owner | Sell | 115K | $6.93 | $795K | 2.8M |
| 2026-05-20 | Zeiher Bernhardt G | Director | Buy | 5K | $5.86 | $29K | 5K |
| 2026-05-04 | Sethuraman Natarajan | President, Research & Develop. | Sell | 26K | $15.39 | $399K | 216K |
| 2026-05-04 | Dowden Nathan J | President & COO | Sell | 15K | $15.33 | $230K | 199K |
| 2026-05-04 | Dowden Nathan J | President & COO | Exercise or conversion | 15K | $1.74 | $26K | 214K |
| 2026-04-01 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 3K | $12.95 | $32K | 119K |
| 2026-03-10 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 11K | $13.02 | $148K | 122K |
| 2026-03-10 | Dowden Nathan J | President & COO | Sell | 12K | $13.05 | $155K | 199K |
| 2026-03-09 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 5K | $13.00 | $66K | 133K |
| 2026-03-09 | Dowden Nathan J | President & COO | Sell | 3K | $13.02 | $41K | 210K |
| 2026-03-04 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 8K | $12.25 | $98K | 138K |
| 2026-03-03 | Sethuraman Natarajan | President, Research & Develop. | Tax withholding | 8K | $11.76 | $89K | 242K |
| 2026-03-03 | WENTWORTH KORY JAMES | Chief Financial Officer | Tax withholding | 6K | $11.76 | $67K | 146K |
| 2026-03-03 | Dowden Nathan J | President & COO | Tax withholding | 14K | $11.76 | $165K | 214K |
| 2026-03-03 | Doshi Dipal | CEO | Tax withholding | 19K | $11.76 | $225K | 526K |
| 2026-03-02 | Sethuraman Natarajan | President, Research & Develop. | Tax withholding | 4K | $11.66 | $45K | 250K |
| 2026-03-02 | WENTWORTH KORY JAMES | Chief Financial Officer | Tax withholding | 3K | $11.66 | $34K | 152K |
| 2026-03-02 | Dowden Nathan J | President & COO | Tax withholding | 7K | $11.66 | $84K | 228K |
| 2026-03-02 | Doshi Dipal | CEO | Tax withholding | 10K | $11.66 | $115K | 545K |
| 2026-03-01 | Sethuraman Natarajan | President, Research & Develop. | Grant | 56K | $0.00 | $0 | 254K |
| 2026-03-01 | WENTWORTH KORY JAMES | Chief Financial Officer | Grant | 45K | $0.00 | $0 | 155K |
| 2026-03-01 | Dowden Nathan J | President & COO | Grant | 56K | $0.00 | $0 | 235K |
| 2026-03-01 | Doshi Dipal | CEO | Grant | 139K | $0.00 | $0 | 555K |
| 2025-11-21 | WENTWORTH KORY JAMES | Chief Financial Officer | Sell | 9K | $9.98 | $89K | 110K |
| 2025-11-20 | BAKER FELIX | TenPercentOwner | Buy | 1K | $9.07 | $11K | 380K |
| 2025-11-20 | BAKER FELIX | TenPercentOwner | Buy | 13K | $9.07 | $121K | 4.7M |
| 2025-11-20 | BAKER FELIX | TenPercentOwner | Buy | 1K | $9.07 | $11K | 381K |
| 2025-11-20 | BAKER FELIX | TenPercentOwner | Buy | 13K | $9.07 | $119K | 4.7M |
| 2025-11-20 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 13K | $9.07 | $119K | 4.7M |
| 2025-11-20 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 1K | $9.07 | $11K | 381K |
| 2025-11-20 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 13K | $9.07 | $121K | 4.7M |
| 2025-11-20 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 1K | $9.07 | $11K | 380K |
| 2025-11-14 | PARMAR KUSH | Director, 10% owner | Sell | 200K | $8.80 | $1.8M | 3.0M |
| 2025-11-14 | 5AM Ventures V, L.P. | 10% owner | Sell | 200K | $8.80 | $1.8M | 3.0M |
| 2025-11-12 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 1K | $7.95 | $8K | 379K |
| 2025-11-12 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 81K | $7.73 | $625K | 4.7M |
| 2025-11-12 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 7K | $7.73 | $57K | 378K |
| 2025-11-12 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 11K | $7.95 | $91K | 4.7M |
| 2025-11-12 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 11K | $7.95 | $91K | 4.7M |
| 2025-11-12 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 1K | $7.95 | $8K | 379K |
| 2025-11-12 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 81K | $7.73 | $625K | 4.7M |
| 2025-11-12 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 7K | $7.73 | $57K | 378K |
| 2025-11-11 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 1K | $7.39 | $8K | 368K |
| 2025-11-11 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 31K | $7.54 | $233K | 4.6M |
| 2025-11-11 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 3K | $7.54 | $21K | 371K |
| 2025-11-11 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 12K | $7.39 | $86K | 4.5M |
| 2025-11-11 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 31K | $7.54 | $233K | 4.6M |
| 2025-11-11 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 3K | $7.54 | $21K | 371K |
| 2025-11-11 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 12K | $7.39 | $86K | 4.5M |
| 2025-11-11 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 1K | $7.39 | $8K | 368K |
| 2025-11-10 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 2K | $7.21 | $17K | 366K |
| 2025-11-10 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 25K | $7.21 | $183K | 4.5M |
| 2025-11-10 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 267 | $7.22 | $2K | 367K |
| 2025-11-10 | Baker Bros. Advisors (GP) LLC | TenPercentOwner | Buy | 3K | $7.22 | $21K | 4.5M |
| 2025-11-10 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 3K | $7.22 | $21K | 4.5M |
| 2025-11-10 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 267 | $7.22 | $2K | 367K |
| 2025-11-10 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 25K | $7.21 | $183K | 4.5M |
| 2025-11-10 | BAKER BROS. ADVISORS LP | 10% owner | Buy | 2K | $7.21 | $17K | 366K |
| 2025-09-02 | Sethuraman Natarajan | President, Research & Develop. | Tax withholding | 2K | $5.43 | $10K | 198K |
| 2025-09-02 | WENTWORTH KORY JAMES | Chief Financial Officer | Tax withholding | 2K | $5.43 | $9K | 119K |
| 2025-09-02 | Dowden Nathan J | President & COO | Tax withholding | 2K | $5.43 | $9K | 179K |
| 2025-09-02 | Doshi Dipal | CEO | Tax withholding | 9K | $5.43 | $47K | 416K |
| 2025-07-09 | 5AM Opportunities I, L.P. | TenPercentOwner | Sell | 7K | $7.50 | $52K | 1.1M |
| 2025-07-09 | 5AM Opportunities I, L.P. | TenPercentOwner | Sell | 20K | $7.50 | $150K | 3.2M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON10 Form 144 notices on file for TRDA worth $6.2M at the prices reported; 1 in the last 90 days worth $1.1M. Latest: 5AM Ventures V, L.P. filed on 2026-08-10 to sell 165,578 shares ($1.1M) from 2026-07-30.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-10 | 5AM Ventures V, L.P.Affiliated stockholder | 166K | $1.1M | 0.427% | 2026-07-30 | Goldman Sachs & Co. LLC |
| 2026-07-30 | 5AM Ventures V, L.P.Affiliated stockholder | 331K | $2.2M | 0.853% | 2026-07-30 | Goldman Sachs & Co. LLC |
| 2026-05-04 | NATARAJAN SETHURAMANOfficer | 26K | $376K | 0.068% | 2026-05-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-04 | NATHAN DOWDENOfficer | 15K | $218K | 0.039% | 2026-05-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-01 | KORY WENTWORTHOfficer | 3K | $32K | 0.007% | 2026-04-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-09 | KORY WENTWORTHOfficer | 16K | $207K | 0.043% | 2026-03-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-09 | NATHAN DOWDENOfficer | 15K | $189K | 0.039% | 2026-03-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-04 | KORY WENTWORTHOfficer | 8K | $95K | 0.021% | 2026-03-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-21 | KORY WENTWORTHOfficer | 9K | $82K | 0.023% | 2025-11-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-14 | 5AM Ventures V, L.P.Affiliated Stockholder | 200K | $1.8M | 0.523% | 2025-11-14 | Goldman Sachs & Co. LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON10 holders report 5% or more of TRDA in their latest filing, all on Schedule 13D (active intent). The largest reported stake is Kush Parmar at 10.8% of the class (4,123,849 shares), filed 2025-11-18 for an event on 2025-11-14.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-10 | 13D/Ano. 1 | ANSBERT GADICKEindividual | 3.9M | 9.9% | 2026-09-08 |
| 2026-09-10 | 13D/Ano. 1 | Todd Foleyindividual | 3.9M | 9.9% | 2026-09-08 |
| 2026-09-10 | 13D/Ano. 1 | LUKE EVNINindividual | 3.9M | 9.9% | 2026-09-08 |
| 2026-09-10 | 13D/Ano. 1 | MPM BioVentures 2018 LLCother entity | 1.9M | 5.0% | 2026-09-08 |
| 2026-09-10 | 13D/Ano. 1 | MPM BioVentures 2014 LLCother entity | 1.9M | 5.0% | 2026-09-08 |
| 2026-09-10 | 13D/Ano. 1 | MPM BioVentures 2018 GP LLCother entity | 1.9M | 4.9% | 2026-09-08 |
| 2026-09-10 | 13D/Ano. 1 | MPM BioVentures 2014 GP LLCother entity | 1.9M | 4.8% | 2026-09-08 |
| 2026-09-10 | 13D/Ano. 1 | MPM BIOVENTURES 2018, L.P.partnership | 1.8M | 4.7% | 2026-09-08 |
| 2026-09-10 | 13D/Ano. 1 | MPM BioVentures 2014, L.P.partnership | 1.8M | 4.5% | 2026-09-08 |
| 2026-09-10 | 13D/Ano. 1 | MPM BioVentures 2014 (B), L.P.partnership | 118K | 0.3% | 2026-09-08 |
| 2026-09-10 | 13D/Ano. 1 | MPM BIOVENTURES 2018 (B), L.P.partnership | 96K | 0.2% | 2026-09-08 |
| 2026-09-10 | 13D/Ano. 1 | MPM Asset Management Investors BV2014 LLCother entity | 61K | 0.2% | 2026-09-08 |
| 2026-09-10 | 13D/Ano. 1 | MPM ASSET MANAGEMENT INVESTORS BV2018 LLCother entity | 36K | 0.1% | 2026-09-08 |
| 2026-08-14 | 13G/Ano. 1 | TCG Crossover GP I, LLCother entity | 1.1M | 2.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | TCG Crossover Fund I, L.P.partnership | 1.1M | 2.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Chen Yuindividual | 1.1M | 2.7% | 2026-06-30 |
| 2025-11-18 | 13D/Ano. 1 | Kush Parmarindividual | 4.1M | 10.8% | 2025-11-14 |
| 2025-11-18 | 13D/Ano. 1 | Andrew J. Schwabindividual | 4.1M | 10.6% | 2025-11-14 |
| 2025-11-18 | 13D/Ano. 1 | 5AM Partners V, LLCother entity | 3.0M | 7.8% | 2025-11-14 |
| 2025-11-18 | 13D/Ano. 1 | 5AM Ventures V, L.P.partnership | 3.0M | 7.8% | 2025-11-14 |
| 2025-11-18 | 13D/Ano. 1 | Scott M. Rocklageindividual | 3.0M | 7.8% | 2025-11-14 |
| 2025-11-18 | 13D/Ano. 1 | 5AM Opportunities I, L.P.partnership | 1.1M | 2.9% | 2025-11-14 |
| 2025-11-18 | 13D/Ano. 1 | 5AM Opportunities I (GP), LLCother entity | 0 | 2.9% | 2025-11-14 |
| 2025-11-14 | 13G/Ano. 5 | T. Rowe Price Associates, Inc.investment adviser | 361K | 0.9% | 2025-09-30 |
13F holders
Tracked managers holding TRDA at their latest 13F. JSON7 of the 30 tracked managers held TRDA at their latest 13F, $15.9M in total at quarter-end prices. Millennium Management is the largest at $5.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 764K | $5.6M | 0.00% | +245K |
| AQR Capital Management | 2026-06-30 | 700K | $5.1M | 0.00% | +620K |
| Citadel Advisors | 2026-06-30 | 394K | $2.9M | 0.00% | +179K |
| Renaissance Technologies | 2026-06-30 | 191K | $1.4M | 0.00% | -11K |
| Two Sigma Investments | 2026-06-30 | 46K | $342K | 0.00% | +2K |
| D. E. Shaw & Co. | 2026-06-30 | 32K | $238K | 0.00% | -47K |
| Point72 Asset Management | 2026-06-30 | 29K | $210K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Entrada Therapeutics reported revenue of $898K, down 53.9% from the same quarter a year earlier, and net loss of $42.8M (-1.01 diluted EPS). In FY 2025 it generated -$128.5M of operating cash flow.
- Cash
- $99.3M
- Equity
- $233.4M
- Total assets
- $298.9M
- Shares outstanding
- 38,936,669
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $898K | -$42.8M | -4762.0% | -1.01 |
| Q1 FY 2026 | 2026-03-31 | $875K | -$39.7M | -4539.1% | -0.95 |
| Q4 FY 2025derived | 2025-12-31 | $1.3M | -$39.2M | -3014.9% | n/a |
| Q3 FY 2025 | 2025-09-30 | $1.6M | -$44.1M | -2734.4% | -1.06 |
| Q2 FY 2025 | 2025-06-30 | $1.9M | -$43.1M | -2210.4% | -1.04 |
| Q1 FY 2025 | 2025-03-31 | $20.6M | -$17.3M | -84.4% | -0.42 |
| Q4 FY 2024derived | 2024-12-31 | $37.4M | $1.1M | 3.0% | n/a |
| Q3 FY 2024 | 2024-09-30 | $19.6M | -$14.0M | -71.7% | -0.35 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $25.4M | -$143.8M | -$128.5M | $1.0M | n/a | n/a |
| FY 2024 | 2024-12-31 | $210.8M | $65.6M | -$41.6M | $3.2M | n/a | n/a |
| FY 2023 | 2023-12-31 | $129.0M | -$6.7M | $139.8M | $5.6M | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | -$94.6M | -$93.8M | $2.9M | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$51.2M | -$50.9M | $4.6M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Entrada Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Entrada Therapeutics (TRDA), SEC CIK 1689375, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-05.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-10.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-10.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-09.JSON and CSV
- Company record
- EDGAR filing index for CIK 1689375Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of TRDA is sold short?
3,271,781 shares were held short at the 2026-10-15 settlement, 8.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is TRDA's daily short volume?
On 2026-11-03, 43,960 of the 149,942 TRDA shares reported to FINRA were sold short, 29.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does TRDA have fails to deliver?
The SEC's latest file shows 47,862 TRDA shares failed to deliver at settlement 2026-10-05. Fails are reported per settlement date and published twice a month with a lag.
Are TRDA insiders buying or selling?
Insiders at TRDA reported 29 open-market sells worth $8.7M in the last 90 days and no open-market buys. Latest filing: MPM BIOVENTURES 2018, L.P. (10% owner) on 2026-09-09.
Have TRDA insiders filed to sell?
10 Form 144 notices on file for TRDA worth $6.2M at the prices reported; 1 in the last 90 days worth $1.1M. Latest: 5AM Ventures V, L.P. filed on 2026-08-10 to sell 165,578 shares ($1.1M) from 2026-07-30.
Who owns 5% or more of TRDA?
10 holders report 5% or more of TRDA in their latest filing, all on Schedule 13D (active intent). The largest reported stake is Kush Parmar at 10.8% of the class (4,123,849 shares), filed 2025-11-18 for an event on 2025-11-14.
What did TRDA report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Entrada Therapeutics reported revenue of $898K, down 53.9% from the same quarter a year earlier, and net loss of $42.8M (-1.01 diluted EPS). In FY 2025 it generated -$128.5M of operating cash flow.
Which tracked 13F managers own TRDA?
7 of the 30 tracked 13F managers held TRDA shares at their latest filing, $15.9M in all. The largest: Izzy Englander's Millennium Management (764K shares, $5.6M), Cliff Asness's AQR Capital Management (700K shares, $5.1M), Ken Griffin's Citadel Advisors (394K shares, $2.9M), Renaissance Technologies (191K shares, $1.4M), Two Sigma Investments (46K shares, $342K), D. E. Shaw & Co. (32K shares, $238K). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.